Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial
      QxMD      Google Scholar   
Citation:
Am. J. Clin. Oncol. vol 35 (5) 418-423
Year:
2012
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
N01 CA035431, U10 CA035269, CA-37404, U10 CA025224-30S2, CA-45450, CA-35195, U10 CA037404, U10 CA063849-16, U10 CA035195, CA-35103, CA-25224, U10 CA037404-21, U10 CA035272-26, U10 CA035272, U10 CA035269-28, U10 CA045450, U10 CA063849, U10 CA035431, UG1 CA189808, CA-35272, CA-35269, U10 CA025224, CA-63849, U10 CA035195-26, U10 CA035431-24, U10 CA035103, U10 CA045450-24  
Corr. Author:
 
Authors:
                   
Primary Study
N0041
Secondary Studies:
Phases:
2
Keywords:
Article